5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-019159-23-GB (EUCTR)	22/12/2010	08/10/2010	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy ...	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy ...	Progressive Supranuclear Palsy MedDRA version: 14.0;Level: PT;Classification code 10036813;Term: Pro ...	Product Name: Davunetide Product Code: AL -108 INN or Proposed INN: Davunetide	Allon Therapeutics Inc	NULL	Not Recruiting			Female: yes Male: yes	300	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;United States;Canada;Australia;Germany;United Kingdom
2	EUCTR2010-019159-23-DE (EUCTR)	08/11/2010	27/08/2010	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy ...	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy ...	Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Pro ...	Product Name: Davunetide Product Code: AL -108 INN or Proposed INN: Davunetide	Allon Therapeutics Inc	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 2/3	France;United States;Canada;Australia;Germany;United Kingdom
3	NCT01110720 (ClinicalTrials.gov)	October 2010	23/4/2010	Study to Evaluate the Safety and Efficacy of Davunetidefor the Treatment of Progressive Supranuclear ...	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy ...	Progressive Supranuclear Palsy	Drug: Davunetide;Drug: Placebo	Allon Therapeutics	NULL	Completed	41 Years	85 Years	Both	313	Phase 2/Phase 3	United States;Australia;Canada;France;Germany;United Kingdom
4	NCT01056965 (ClinicalTrials.gov)	January 2010	21/1/2010	Davunetide (AL-108) in Predicted Tauopathies - Pilot Study	A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide(NAP, AL-108) in Pre ...	Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkins ...	Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray	University of California, San Francisco	NULL	Completed	40 Years	85 Years	All	12	Phase 1	United States

First Previous1Next Last